WebBisphosphonates are first-line agents used for the treatment of osteoporosis in postmenopausal women and men. Although their efficacy in the reduction of vertebral, non-vertebral and hip fracture risk has been established, some concerns have arisen associated with their long-term use. WebBisphosphonate treatment should be reviewed after 5 years of treatment with alendronic acid, risedronate sodium or ibandronic acid, and after 3 years of treatment with …

Bisphosphonates: How Long Is Enough? - Medscape

WebThe BMD and bone marker changes showed some residual effect for at least five years after subjects had ended a five-year course of therapy. Continuing alendronate treatment for five years reduced the risk of clinical vertebral fracture. how to take good pictures of jewelry

Quality statement 4: Long-term follow-up Osteoporosis

WebMay 31, 2012 · Patients with low bone mineral density at the femoral neck (T score below −2.5) after 3 to 5 years of treatment are at the highest risk for vertebral fractures and therefore appear to benefit ... WebDec 16, 2024 · “In this study of women who completed 5 years of bisphosphonate treatment, completing an additional 5 years of treatment was not associated with a reduction in hip fracture risk; the potential hip fracture benefit for continuing 2 additional years but not for 5 additional years should be further studied,” the authors write. WebAug 15, 2015 · The optimal length of oral bisphosphonate therapy is unknown. One study found that women who take alendronate for five years followed by five years of placebo … ready set create